A Study of MRx-4DP0004 in Asthma

Summary

This is a multicentre, phase I/II, double-blind, placebo-controlled study of MRx-4DP0004 in participants taking long-term medication for asthma. Participants will take two capsules of MRx-4DP0004 twice daily in addition to their existing asthma medication for 12 weeks. Safety and tolerability and immune modulatory effects of MRx-4DP0004 will be assessed throughout the study.

Timeline

Start

2019-07-04

Primary completion

2023-04-26

Completion

2023-04-26

Outcome

Outcome not reported

Stopped: “Sponsor insolvency”

Drugs

Indications